Kylla has been instumental in helping a startup in diagnostic-psychiatry secure the finance it needs for its research into a new technique for diagnostics. The tool it is developing could lead to a more timely and substantiated choice of treatment and medication. By securing venture capital financing, we enabled the venture to start confirmation studies and begin design and production of the diagnostic material. With a secure financial platform, the company expects to grow to 12 employees over the next few years and to successfully bring its technology to the market.
The expected exit value of this venture is €50 million.
